0001177648-18-000007.txt : 20180213
0001177648-18-000007.hdr.sgml : 20180213
20180213182837
ACCESSION NUMBER: 0001177648-18-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180212
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adda Nathalie
CENTRAL INDEX KEY: 0001646976
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 18605704
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-02-12
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001646976
Adda Nathalie
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Sr. VP & Chief Medical Officer
Common Stock
2018-02-12
4
A
0
2500
0
A
3808
D
Common Stock
2018-02-12
4
A
0
6028
0
A
9836
D
Common Stock
2018-02-12
4
F
0
2566
76.845
D
7270
D
Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018.
Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018.
Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
/s/ Nathaniel S. Gardiner as attorney-in-fact
2018-02-13